Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.
Langer
R M
RM
Division of Immunology and Organ Transplantation, University of Texas-Houston, Houston, Texas, USA.
Hong
D M
DM
Katz
S M
SM
Van Buren
C T
CT
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005006:Ethnicity; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000145:classification / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D019520:Living Donors; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins; D012189:Retrospective Studies; D020123:Sirolimus / Q000627:therapeutic use*; D013781:Texas
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D002784:Cholesterol; D000077552:Basiliximab; D003404:Creatinine; D011241:Prednisone; D020123:Sirolimus